Strong Satisfaction Levels with Adalimumab Biosimilar Seen A

This new analysis on IBD patients initiating biologic therapy with the biosimilar ABP 501 indicates that the drug’s lower cost and efficacy may lead to greater use.

Related Keywords

Spain , Germany , Thousand Oaks , California , United States , United Kingdom , Italy , France , , Amgen Inc , Disease Specific Programme , Ran Jin , Specific Programme , Work Productivity , Activity Impairment , Ibd , Inflammatory Bowel Disease , Abp 101 , Biosimilar , Adalimumab ,